Skip to main content
TipRanks
Go Ultimate75% OFF

Equillium (0FY) Stock Price & Analysis

0 Followers

0FY Stock Chart & Stats

€1.21€0.00(-2.82%)
At close: 5:30 PM GMT+1
€1.75€2€2.25€2.5May 13May 28Jun 18Aug 11
Day’s Range
EUR 1.21 - EUR 1.23
52-Week Range
EUR 0.69 - EUR 2.81
Previous Close
EUR 1.24
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 96.34M
Enterprise Value
EUR 129.32M
Total Cash (Recent Filing)
EUR 53.32M
Total Debt (Recent Filing)
EUR 765.00K
Price to Earnings (P/E)
―
Beta
-1.33
Next Earnings
Mar 24, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Minimal debt reduces financing pressure and preserves flexibility while Equillium funds clinical development. The increases in equity and assets versus 2025 provide a stronger capital base, although that base has not yet generated positive returns.

Extended Cash Runway

The additional capital gives Equillium a longer operating horizon to advance EQ504 and pursue planned studies without relying immediately on another financing. A runway extending into 2029 improves execution capacity and reduces near-term funding risk.

Clinical Pipeline Progress

Moving EQ504 into a controlled Phase 1 study is a meaningful development milestone because safety, pharmacokinetic, pharmacodynamic, and tissue-biomarker data can support later proof-of-concept work. This advances the pipeline beyond preclinical development.

Bears Say

Absent Recent Revenue

The complete absence of recent revenue weakens earnings visibility and shows that Equillium is not currently funding operations through commercial sales. Until revenue returns, financial progress remains dependent on clinical milestones and access to external capital.

Persistent Cash Burn

Sustained negative operating and free cash flow means the business consumes cash while advancing its pipeline rather than generating internal funding. Continued burn increases dependence on financing and can constrain development choices if capital access weakens.

Negative Shareholder Returns

A deeply negative return on equity indicates that the capital invested in Equillium is currently supporting losses rather than creating profitable output. Persistent negative returns can limit the company’s ability to compound value without successful clinical and commercial execution.

Equillium News

0FY FAQ

What was Equillium’s price range in the past 12 months?
Equillium lowest stock price was €0.69 and its highest was €2.81 in the past 12 months.
What is Equillium’s market cap?
Equillium’s market cap is €96.34M.
When is Equillium’s upcoming earnings report date?
Equillium’s next earnings report is estimated for Mar 24, 2027 (not yet confirmed), which is in 128 days.
How were Equillium’s earnings last quarter?
Equillium released its earnings results on Nov 12, 2026. The company reported -€0.036 earnings per share for the quarter, beating the consensus estimate of -€0.044 by €0.008.
Is Equillium overvalued?
According to Wall Street analysts Equillium’s price is currently Undervalued.
Does Equillium pay dividends?
Equillium does not currently pay dividends.
What is Equillium’s EPS estimate?
Equillium’s EPS estimate is -0.05.
How many shares outstanding does Equillium have?
Equillium has 82,324,700 shares outstanding.
What happened to Equillium’s price movement after its last earnings report?
Equillium reported an EPS of -€0.036 in its last earnings report, beating expectations of -€0.044. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Equillium?
Hedge funds hold Equillium shares: the largest hedge-fund position in Equillium is 222,573,855 shares.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology